# OnCo record paper-keynote-942-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-942-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-942-lancet-2024" ;
  schema:name "KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery"@en ;
  schema:description "A vaccine custom-made from each patient's own tumour mutations, given with pembrolizumab after surgery for high-risk melanoma, reduced recurrence by about 44% compared with pembrolizumab alone in a mid-sized randomised trial, the first sign that personalised cancer vaccines can work."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-942-lancet-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=mRNA-4157+V940+pembrolizumab+melanoma+KEYNOTE-942+Lancet>, <https://clinicaltrials.gov/study/NCT03897881> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)02268-7> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Weber JS, Carlino MS, Khattak A, et al." ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/moderna/>, <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/interpath-001/> ;
  onco:people <https://onco.cc/people/ryan-sullivan/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/lancet/> .